Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., has announced the signing of a binding term sheet with Modulant Biosciences LLC. This agreement outlines the terms for a future definitive licensing arrangement, granting Modulant exclusive global rights to develop and commercialize EL-22 for animal health applications. This collaboration marks a strategic opportunity for Northstrive to monetize the intellectual property of EL-22, potentially transforming it into a long-term revenue-generating asset. The license allows Modulant to utilize EL-22 in various animal health applications, including as a feed additive, with the exception of the Republic of Korea. Modulant, led by seasoned biotechnology executive Tom Campi, will also have the right to sublicense the technology globally. Financial terms include revenue sharing, where Northstrive will receive a percentage of revenues until a specified limit, after which the royalty rate will decrease. The parties aim to finalize the definitive licensing agreement in the coming months.